Connect with us
Alfasigma has acquired the marketing rights for Jyseleca, a JAK1 inhibitor drug used for rheumatoid arthritis and ulcerative colitis, following European Medicines Agency approval. This acquisition...
Alfasigma, an Italian pharmaceutical company, absorbed Galapagos' Spanish subsidiary in September after board restructuring in June. The merger required regulatory clearance, which was not fully met,...
Alfasigma's Spanish subsidiary is expanding its facilities in Tortosa, Barcelona, to increase production capacity. The subsidiary, created in 2015 through the merger of Sigma-Tau and Alfa...
As part of the transaction, Galapagos will also transfer to Alfasigma the European and U.K. marketing authorizations and related commercial, medical, and development activities, as well...